Caristo Diagnostics

Caristo Diagnostics is a medical imaging company spun out from the University of Oxford’s Department of Cardiovascular Medicine in June 2018.

The Company is commercialising a novel imaging biomarker for the prediction of cardiovascular disease (CVD) risk which is analysed on CT scans of the heart. In clinical studies, this novel biomarker (Fat Attenuation Index or FAI™) has been shown to be accurate in predicting heart attacks and cardiac death, including in those patients deemed low risk by current methods. Patent applications have been made on the core IP and a number of papers covering the technology have been published in high-impact journals.

Visit website